NEWS IN PEDIATRIC GASTROENTEROLOGY PHARMACOLOGY
Biologics beyond anti-TNFs
Institute for Maternal and Child Health IRCCS Burlo Garofolo
The need to offer a therapeutic alternative to patients who are not responsive to anti-TNF biologics and the understanding of the pathogenetic mechanisms of inflammatory bowel diseases have led to the development of new biological drugs. To date, the main new biologics include vedolizumab, an anti-integrin antibody that inhibits leukocyte migration, and ustekinumab, an anti IL12 / IL 23 antibody. Trials on new biologics and non-biological molecules are ongoing.